

2A.6

CARLES AND AND AND AND AND AND AND	
GOOD MANUFACTUR	
	SIGNATURE, AFFIXED ON THE UNDERLYING DOCUMENT, OF:
	I STANTION I
	TOO GERES COMMERCE ET
Exporting (certifying) country: CANADA	LE MINISTÈRE DES AFFAIRES ETRANGERES, COMMERCE ET
Importing (requesting) country: TURKEY	SIGNATURE, APPOSÉE SUR LE DOCUMENT SOUS-JACENT, DE:
importing (requesting) country.	Facelia Mana, trans
1. Name and dosage form of the product:	FOR THE DEPUTY MINISTER OF FOREIGN AFFAIRS POUR CE
COLUMNON	SOUS-MINISTRE DES AFFAIRES ETRA BERES.
SOLUTION	FEB 08 2024
1.1 Active ingredient(s) <sup>2</sup> and amount(s) per	unit dose: 3 /// Tina Wishak
	OCE NOT ALL DATE THE CONTENT OF THE
For complete composition including exci	pients, see attached Tour Ja No
	Wedgement to
1.2 Is this product licensed to be placed of	on the market for use in the exporting country? 5 N/A
If YES, continue with section 2A and leave section 3. If NO, leave question 1.3 and section 2A blank and	
1.3 Is this product actually on the market	in the exporting country? N/A
THIS CERTIFICATE DOES NOT RELATE TO ANY	-m one empereums comment.
	_
2A.1 Number of product license and date of	issue:
2A.2 Product license holder (name and addres	s):
2A.3 Status of license holder: 8	
2A.3.1 For categories (B) and (C) the name and	address of the manufacturer producing the dosage form is:
2A.4 Is a summary basis for approval appende	d ? 10 Not Applicable
2A.5 Is the attached product information com	11

# T.C. Ottava Büyükelçihği

Applicant for certificate, if different from license holder (name and address):

Işbu belgede, Kanada yetkili makamlarınca yapılan tasdik işlemindeki imza ve mühürün, Kuneda Dızı'nıcı Bedindiği. A ait olduğu metne şamil olmamak üzere onavlanın 12-2-2021

Declared original by

**BRANDON ROBERT REINHART** Barrister, Solicitor & Notary Public





2B.1 Applicant for certificate (name and address):

SAOL THERAPEUTICS RESEARCH LIMITED
PETER STREET, UNIT G04
ADELAIDE CHAMBERS, DUBLIN
DUBLIN 8, IRELAND

CANADIAN REPRESENTATIVE: REGCON SOLUTIONS (CANADA) INC. 359 JANENE COURT MISSISSAUGA, ON CANADA, L5A 3Z2

2B.2 Status of applicant: 8 C

2B.2.1 For categories (B) and (C) the name and address of the manufacturer producing the dosage form is:

FABRICATING, PACKAGING, LABELLING AND TESTING SITE:

EMERGENT BIOSOLUTIONS CANADA INC. 155 INNOVATION DRIVE WINNIPEG, MB CANADA, R3T 5Y3

2B.3 Why is marketing authorization lacking?

2B.4 Remarks: 3 GMP CERTIFICATE

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced?  $^{14}$  Yes

If NO or NOT APPLICABLE, proceed to question 4

3.1 Periodicity of routine inspections (years):

3.2 Has the manufacture of this type of dosage form been inspected? Yes

3.3 Do the facilities & operations conform to GMP as recommended by the WHO?  $^{15}$  Yes

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?  $^{16}$  Yes

If NO, explain:

### Address of certifying authority

Regulatory Operations and Enforcement Branch Health Product Compliance Directorate 200 Eglantine Driveway, Tunney's Pasture Ottawa, Ontario K1A 0K9

> Digitally signed by Negus, Caitlin DN: C=CA, OU=HC-SC, O=GC,

Cattlin Negvo — CN="Negus, Caitlin", E=caitlin.negus@canada.

ca

Date: 2021-02-02 14:19: 34

Name of authorized person Caitlin Negus

Date: 2021-02-01

This certificate expires 1 year from the date of issue



Signature:



# Explanatory Notes

- This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
- 2. Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.
- 3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
- 4. Details of quantitative composition are preferred but their provision is subject to the agreement of the product-licence holder.
- 5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.
- 6. Sections 2A and 2B are mutually exclusive.
- 7. Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.
- 8. Specify whether the person responsible for placing the product on the market:
  - a. manufactures the dosage form;
  - b. packages and/or labels a dosage form manufactured by an independent company; or
  - c. is involved in none of the above.
- 9. This information can only be provided with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.
- 10. This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.
- 11. This refers to product information approved by the competent national regulatory authority, such as Summary Product Characteristics (SPC)
- 12. In this circumstance, permission for issuing the certificate is required from the product-licence holder. This permission has to be provided to the authority by the applicant.
- 13. Please indicate the reason that the applicant has provided for not requesting registration.
  - a. the product has been developed exclusively for the treatment of conditions - particularly tropical diseases - not endemic in the country of export;
  - b. the product has been reformulated with a view to improving its stability under tropical conditions;





- c. the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
- d. the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
- e. any other reason, please specify.
- 14. Not applicable means the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
- 15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).
- 16. This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.





Regulatory Operations and Enforcement Branch Health Product Compliance Directorate Jeanne Mance Bldg, 13th Floor 200 Eglantine Driveway Ottawa, ON K1A 0K9 Mail Stop: 1913C

# January 18th, 2021

TO WHOM IT MAY CONCERN,

## RE: Health Canada authorized signatories for CPP and GMP Certificates

This letter authorizes the electronic issuance of a Certificate of Pharmaceutical Product (CPP) or a Good Manufacturing Practices (GMP) Certificate by Health Canada. The purpose of an electronic certificate is to allow Health Canada to meet the requirements of the voluntary agreement set out in the WHO Certification Scheme on the Quality of Pharmaceutical Products during this period where paper-based certificates are unavailable. This certificate provides assurance to importing countries that the pharmaceutical products they will be importing are safe, effective, and of good quality.

A CPP is issued for human drugs (pharmaceutical, biological and radiopharmaceutical) as well as for veterinary drugs (food-producing animals and non-food producing animals).

Electronic versions of these certificates will now be issued to adapt to the current pandemic context and to provide this critical service through an efficient and streamlined process.

As the Director of the Health Product Inspection and Licensing Division within the Health Product Compliance Directorate of Health Canada, I delegate authority to the following individuals to sign electronic CPPs and electronic GMP Certificates and can attest to their identity and responsibilities within Health Canada.

#### Camille Bienvenue

Corporate Regulatory Compliance and Enforcement Advisor/ Conseillère ministérielle en conformité et application de la loi

Drug Establishment Licensing Unit/ Unité des licences d'établissement pour les produits pharmaceutiques

Health Product Compliance Directorate / ...

Health Canada/ Santé Canada

#### **ESignature**

Digitally signed by Bienvenue, Camille DN: C=CA, O=GC, Caville Sienvenue OU=HC-SC, CN="

Bienvenue, Camille" Date: 2021-01-08 08:29:





#### **Caitlin Negus ESignature** Corporate Regulatory Compliance and Digitally signed by Enforcement Advisor / Conseillère Negus, Caitlin ministérielle en conformité et application de DN: C=CA, OU=HC-SC, O=GC, la loi Catlin Negra CN="Negus, Caitlin", Drug Establishment Licensing Unit / Unité E=caitlin.negus@canada des licences d'établissement pour les Date: 2021-01-08 07:39: produits pharmaceutiques 49 Health Product Compliance Directorate / ... Health Canada / Santé Canada

If a regulatory authority in an importing country has questions with respect to the authenticity, integrity or validity of an electronic certificate issued by Health Canada, they can contact the Drug Establishment Licensing Unit directly at <a href="https://hc.cpp.questions.sc@canada.ca">hc.cpp.questions.sc@canada.ca</a>. The Drug Establishment Licensing Unit will respond by providing an exact copy (electronically marked as duplicate) of the electronic certificate directly to the importing authority.

For any further inquires, please also contact <a href="hc.cpp.questions.sc@canada.ca">hc.cpp.questions.sc@canada.ca</a>.

Regards,

Dr. Kim Godard

Director, Health Product Inspection and Licensing Health Product Compliance Directorate Regulatory Operations and Enforcement Branch Health Canada

